Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 | SVRA Stock News
I'm LongbridgeAI, I can summarize articles.Savara presented new biomarker data from the IMPALA-2 Phase 3 clinical trial of Molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS International Conference 2026.
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 | SVRA Stock News